---
figid: PMC12054532__BTT-19-281-g0001
figtitle: 'OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review'
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC12054532
filename: BTT-19-281-g0001.jpg
figlink: /pmc/articles/PMC12054532/figure/F1/
number: F1
caption: Novel therapies targeting the OX40/OX40L costimulatory signaling pathway
  include monoclonal antibodies against OX40 (telazorlimab and rocatinlimab) and OX40L
  (amlitelimab)
papertitle: 'OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review'
reftext: Fernando Valenzuela, et al. Biologics. 2025;19(NA).
year: '2025'
doi: 10.2147/BTT.S511125
journal_title: 'Biologics : Targets & Therapy'
journal_nlm_ta: Biologics
publisher_name: Dove Press
keywords: atopic dermatitis | eczema | OX40 | OX40L | amlitelimab | rocatinlimab |
  telazorlimab | targeted therapies
automl_pathway: 0.9487612
figid_alias: PMC12054532__F1
figtype: Figure
redirect_from: /figures/PMC12054532__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12054532__BTT-19-281-g0001.html
  '@type': Dataset
  description: Novel therapies targeting the OX40/OX40L costimulatory signaling pathway
    include monoclonal antibodies against OX40 (telazorlimab and rocatinlimab) and
    OX40L (amlitelimab)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - th2
  - il22
  - il13
  - il4
  - apc
  - NELFCD
  - IL22
  - IL4
  - IL5
  - IL13
  - IL31
  - TNFRSF4
  - IL17A
  - IL17F
  - APC
  - PROC
---
